首页> 美国卫生研究院文献>Cell Transplantation >An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells
【2h】

An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells

机译:地塞米松对诱导的多能干细胞来源的间充质干细胞免疫抑制功能影响的体内和体外研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) represent a promising cell source for patient-specific cell therapy. We previously demonstrated that they display an immunomodulatory effect on allergic airway inflammation. Glucocorticoids are powerful anti-inflammatory compounds and widely used in the therapy of allergic diseases. However, the effect of glucocorticoids on the immunomodulatory function of iPSC-MSCs remains unknown. This study aimed to determine the effect of dexamethasone (Dex) on the immunomodulatory function of iPSC-MSCs in vitro and in vivo. A total of three human iPSC-MSC clones were generated from amniocyte-derived iPSCs. Anti-CD3/CD28-induced peripheral blood mononuclear cell (PBMC) proliferation was used to assess the effect of Dex on the immunoinhibitory function of iPSC-MSCs in vitro. Mouse models of contact hypersensitivity (CHS) and allergic airway inflammation were induced, and the levels of inflammation in mice were analyzed with the treatments of iPSC-MSCs and Dex, alone and combined. The results showed that Dex did not interfere with the immunoinhibitory effect of iPSC-MSCs on PBMC proliferation. In CHS mice, simultaneous treatment with Dex did not affect the effect of iPSC-MSCs on the inflammation, both in regional draining lymph nodes and in inflamed ear tissue. In addition, co-administration of iPSC-MSCs with Dex decreased the local expression of interferon (IFN)-γ and tumor necrosis factor (TNF)-α in the ears of CHS mice. In the mouse model of allergic airway inflammation, iPSC-MSC treatment combined with Dex resulted in a similar extent of reduction in pulmonary inflammation as iPSC-MSCs or Dex treatment alone. In conclusion, Dex does not significantly affect the immunomodulatory function of iPSC-MSCs both in vitro and in vivo. These findings may have implications when iPSC-MSCs and glucocorticoids are co-administered.
机译:诱导多能干细胞衍生的间充质干细胞(iPSC-MSC)代表了一种针对患者特异性细胞治疗的有希望的细胞来源。我们先前证明它们对过敏性气道炎症表现出免疫调节作用。糖皮质激素是有效的抗炎化合物,广泛用于过敏性疾病的治疗。但是,糖皮质激素对iPSC-MSCs免疫调节功能的影响仍然未知。这项研究旨在确定地塞米松(Dex)对iPSC-MSCs体外和体内免疫调节功能的影响。从羊膜细胞衍生的iPSC共生成了三个人类iPSC-MSC克隆。抗CD3 / CD28诱导的外周血单个核细胞(PBMC)增殖用于评估Dex对体外iPSC-MSCs免疫抑制功能的影响。诱导了小鼠接触性超敏反应(CHS)和过敏性气道炎症模型,并单独或联合使用iPSC-MSC和Dex来分析小鼠的炎症水平。结果表明,Dex不会干扰iPSC-MSC对PBMC增殖的免疫抑制作用。在CHS小鼠中,同时进行Dex治疗并不会影响iPSC-MSC在炎症区域的引流淋巴结和耳部发炎组织中的作用。此外,iPSC-MSC与Dex并用会降低CHS小鼠耳朵中干扰素(IFN)-γ和肿瘤坏死因子(TNF)-α的局部表达。在过敏性气道炎症的小鼠模型中,iPSC-MSC治疗与Dex联合使用可导致与iPSC-MSCs或单独进行Dex治疗相似程度的肺部炎症减轻。总之,Dex在体外和体内均不会显着影响iPSC-MSC的免疫调节功能。当联合使用iPSC-MSC和糖皮质激素时,这些发现可能会有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号